

# Enrique Grande

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2458895/publications.pdf>

Version: 2024-02-01

133  
papers

5,161  
citations

218677

26  
h-index

91884

69  
g-index

138  
all docs

138  
docs citations

138  
times ranked

6767  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2017, 376, 125-135.	27.0	2,206
2	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1547-1557.	13.7	546
3	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 14-23.	1.6	258
4	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
5	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	27.6	103
6	Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 569-579.	4.1	99
7	Targeting HIF-2 $\hat{\pm}$ in clear cell renal cell carcinoma: A promising therapeutic strategy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 117-123.	4.4	90
8	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for $\hat{\pm}$ 24 weeks in Europe. <i>European Urology</i> , 2018, 74, 37-45.	1.9	86
9	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	7.7	80
10	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup> Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
11	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxalisib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1471-1476.	6.4	74
12	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. <i>Cancer</i> , 2019, 125, 1301-1312.	4.1	68
13	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	6.4	66
14	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na <sup>+</sup> -ve Advanced Pancreatic Neuroendocrine Tumors. <i>Oncologist</i> , 2018, 23, 766-e90.	3.7	59
15	Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 307-318.	3.2	49
16	Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies. <i>Journal of Thyroid Research</i> , 2012, 2012, 1-10.	1.3	48
17	BRAF Mutated Colorectal Cancer: New Treatment Approaches. <i>Cancers</i> , 2020, 12, 1571.	3.7	44
18	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 295-305.	4.7	43

#	ARTICLE	IF	CITATIONS
19	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" International Journal of Molecular Sciences, 2019, 20, 1901.	4.1	41
20	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews, 2015, 34, 823-842.	5.9	39
21	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology, 2018, 73, 462-468.	1.9	36
22	Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treatment Reviews, 2018, 69, 164-176.	7.7	35
23	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2014, 40, 1230-1238.	7.7	34
24	Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer, 2014, 14, 779.	2.6	33
25	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncology, 2017, 13, 615-624.	2.4	32
26	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 5981.	3.7	31
27	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. Critical Reviews in Oncology/Hematology, 2014, 92, 83-106.	4.4	30
28	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). European Journal of Endocrinology, 2017, 177, 309-317.	3.7	30
29	Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.. Journal of Clinical Oncology, 2020, 38, 5011-5011.	1.6	26
30	Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer, 2015, 15, 495.	2.6	25
31	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). Oncologist, 2020, 25, 745-e1265.	3.7	25
32	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer, 2021, 19, e84-e91.	1.9	23
33	Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist, 2016, 21, 701-707.	3.7	22
34	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	4.4	22
35	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. Oncologist, 2019, 24, 1375-1383.	3.7	22
36	Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2016, 63, e17-e24.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). <i>British Journal of Cancer</i> , 2019, 121, 537-544.	6.4	18
38	Rogaratnib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.. <i>Journal of Clinical Oncology</i> , 2018, 36, 494-494.	1.6	18
39	Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 47-53.	5.9	17
40	sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4140-4140.	1.6	17
41	A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. <i>Journal of Research in Medical Sciences</i> , 2013, 18, 623-5.	0.9	17
42	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	3.1	17
43	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	15
44	Emerging use of everolimus in the treatment of neuroendocrine tumors. <i>Cancer Management and Research</i> , 2017, Volume 9, 215-224.	1.9	14
45	ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13044.	2.6	14
46	Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. <i>World Journal of Clinical Oncology</i> , 2017, 8, 100.	2.3	14
47	Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017, 19, 72.	4.0	13
48	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	2.6	13
49	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. <i>Cancer Treatment Reviews</i> , 2018, 70, 209-222.	7.7	12
50	The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). <i>Targeted Oncology</i> , 2019, 14, 15-32.	3.6	12
51	Sunitinib and Evofosfamide (<sc>TH</sc>-302) in Systemic Treatment-Na <sup>+</sup> ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <sc>GETNE</sc>-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	3.7	12
52	Updated efficacy and &gt; 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4515-4515.	1.6	12
53	Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103683.	4.4	12
54	Circulating Levels of the Interferon- $\beta$ -Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. <i>Cancers</i> , 2021, 13, 2849.	3.7	10

#	ARTICLE	IF	CITATIONS
55	Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review. <i>World Journal of Gastroenterology</i> , 2020, 26, 4537-4556.	3.3	10
56	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. <i>Oncotarget</i> , 2018, 9, 36894-36905.	1.8	9
57	Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103731.	4.4	9
58	Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2011, 22, 477-479.	1.4	8
59	Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881982821.	3.2	8
60	Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. <i>Oncologist</i> , 2019, 24, e1315-e1320.	3.7	8
61	Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a drug cocktail in patients with MET dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2867-2878.	2.4	8
62	New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 457-467.	2.4	7
63	Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 493-498.	1.9	7
64	Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4951.	4.1	7
65	Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). <i>Endocrinología Y Nutrición: Organó De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2015, 62, e37-e46.	0.8	6
66	Inconclusive Analysis of the Connection Between Secondary Hematologic Malignancies and Radioiodine Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 1882-1883.	1.6	6
67	Novel Tyrosine Kinase Targets in Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 747.	4.1	6
68	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021, 16, 625-632.	3.6	6
69	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. <i>Neuroendocrinology</i> , 2022, 112, 88-100.	2.5	6
70	Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). <i>Clinical and Translational Oncology</i> , 2010, 12, 481-492.	2.4	5
71	A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 279-279.	1.6	5
72	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4588-TPS4588.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	1.9	5
74	Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. <i>Clinical and Translational Oncology</i> , 2011, 13, 798-804.	2.4	4
75	An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). <i>Rare Cancers and Therapy</i> , 2015, 3, 13-33.	0.2	4
76	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4557-4557.	1.6	4
77	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 323-323.	1.6	4
78	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. <i>Targeted Oncology</i> , 2016, 11, 129-141.	3.6	3
79	Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 573-579.	2.4	3
80	Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 831-840.	2.4	3
81	Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 1-8.	0.4	3
82	Correlation of VEGFR2 expression in tumor tissue with longer progression-free survival in patients with neuroendocrine tumors (NETs) treated with pazopanib.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15154-e15154.	1.6	3
83	Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3527-3527.	1.6	3
84	Adherence to oral therapies in metastatic castration resistance (m CRPC) prostate cancer patients: The ADOPTA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18014-e18014.	1.6	3
85	A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the) Tj ETQq1 1 @.784314 3gBT /Ov		
86	A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities. <i>Current Pharmaceutical Design</i> , 2014, 20, 6644-6651.	1.9	3
87	Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. <i>Autopsy and Case Reports</i> , 2018, 8, e2018005.	0.6	3
88	Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.. <i>Journal of Clinical Oncology</i> , 2019, 37, 637-637.	1.6	3
89	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. <i>Oncologist</i> , 2022, 27, e328-e339.	3.7	3
90	Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 497.	2.4	3

#	ARTICLE	IF	CITATIONS
91	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study. <i>European Urology</i> , 2022, 81, 623-624.	1.9	3
92	Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors. <i>Kidney Cancer</i> , 2019, 3, 41-50.	0.4	2
93	Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100039.	0.1	2
94	Coming of Age of Immunotherapy of Urothelial Cancer. <i>Targeted Oncology</i> , 2021, 16, 283-294.	3.6	2
95	Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): Data from one Spanish cohort.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14671-e14671.	1.6	2
96	Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6027-6027.	1.6	2
97	A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS479-TPS479.	1.6	2
98	Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation. <i>Oncotarget</i> , 2020, 11, 2137-2140.	1.8	2
99	High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1001-1013.	3.0	2
100	Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16074-e16074.	1.6	1
101	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatmentâ€”ABIDO-SOGUG Trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16022-e16022.	1.6	1
102	Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, e17553-e17553.	1.6	1
103	Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naïve castration-resistant prostate cancer: Exploratory results from PREMIEREâ€”A SOGUG trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5052-5052.	1.6	1
104	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5577-5577.	1.6	1
105	How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, e16504-e16504.	1.6	1
106	Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 165-165.	1.6	1
107	Temozolamide plus capecitabine as salvage treatment for patients with advanced neuroendocrine tumors (NETs) in the community setting.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15169-e15169.	1.6	1
108	Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3651-TPS3651.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study. GETHI 2013-01.. Journal of Clinical Oncology, 2015, 33, TPS5612-TPS5612.	1.6	1
110	Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. Journal of Clinical Oncology, 2015, 33, e14524-e14524.	1.6	1
111	Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?. World Journal of Clinical Oncology, 2016, 7, 149.	2.3	1
112	Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?. Journal of Clinical Oncology, 2022, 40, e16512-e16512.	1.6	1
113	Living with Cancer: Through the Eyes of the Patient and the Physician. Oncology and Therapy, 2016, 4, 183-187.	2.6	0
114	In Reply. Oncologist, 2020, 25, e1259-e1259.	3.7	0
115	Molecular characterization of nonpancreatic neuroendocrine neoplasms (NENS): First description of mutations in the tumor suppressor gene (TSG) <i>SMARCB1</i> in NENS of colorectal origin using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 4135-4135.	1.6	0
116	Epithelial-mesenchymal transition markers in metastatic transitional cell carcinoma (mTCC) patients under vinflunine treatment.. Journal of Clinical Oncology, 2013, 31, e15532-e15532.	1.6	0
117	Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure to one cisplatin-based systemic therapy in clinical practice.. Journal of Clinical Oncology, 2014, 32, 332-332.	1.6	0
118	Study of the gastroenteropancreatic neuroendocrine tumor (gep-net) microenvironment beyond angiogenesis: The role of lysyl oxidase-like 2 (LOXL2).. Journal of Clinical Oncology, 2014, 32, 4109-4109.	1.6	0
119	Pazopanib activity in pancreatic neuroendocrine tumors (pNETs).. Journal of Clinical Oncology, 2014, 32, e15171-e15171.	1.6	0
120	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.. Journal of Clinical Oncology, 2014, 32, TPS5626-TPS5626.	1.6	0
121	Soft tissue sarcomas: A challenge for oncology.. Journal of Clinical Oncology, 2014, 32, e21512-e21512.	1.6	0
122	Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03).. Journal of Clinical Oncology, 2014, 32, 5558-5558.	1.6	0
123	Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2014, 32, e17015-e17015.	1.6	0
124	Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.. Journal of Clinical Oncology, 2014, 32, TPS5096-TPS5096.	1.6	0
125	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. Journal of Clinical Oncology, 2014, 32, e15019-e15019.	1.6	0
126	Prognostic factors in advanced gastric cancer after second-line treatment.. Journal of Clinical Oncology, 2015, 33, 201-201.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15061-e15061.	1.6	0
128	Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy: PREMIERE-SOGUG Trial.. Journal of Clinical Oncology, 2015, 33, TPS5073-TPS5073.	1.6	0
129	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.. Journal of Clinical Oncology, 2016, 34, 5058-5058.	1.6	0
130	Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.. Journal of Clinical Oncology, 2016, 34, TPS2598-TPS2598.	1.6	0
131	A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).. Journal of Clinical Oncology, 2017, 35, 285-285.	1.6	0
132	Association of androgen receptor (AR) gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Exploratory results from the PREMIERE trialâ€”On behalf of SOGUG.. Journal of Clinical Oncology, 2017, 35, 5016-5016.	1.6	0
133	Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome.. Journal of Clinical Oncology, 2017, 35, e15692-e15692.	1.6	0